EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers

Kevin A David iD, Suchitra Sundaram, Seo-Hyun Kim, Ryan Vaca, Yong Lin, Samuel Singer, Mary-Kate Malecek iD, Jordan Carter, Adam Zayac iD, Myung Sun Kim, Nishitha Reddy, Douglas Ney iD und 34 weitere

American Journal of Hematology · 2023

DOI: 10.1002/ajh.26919 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2023. Verfasst von Kevin A David und 45 weiteren Autor:innen. Beteiligte Einrichtung: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA. Hauptthemen laut MEDLINE: Lymphoma, Central Nervous System Neoplasms. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is a paucity of large‐scale data delineating outcomes and prognostication of older patients with primary central nervous system lymphoma (PCNSL). We retrospectively analyzed 539 newly‐diagnosed PCNSL patients ages ≥60 years across 20 U.S. academic centers. The median age was 70 years (range 60–88); at least one geriatric syndrome was present in 46%; the median Cumulative Index Ratings Scale‐Geriatrics (CIRS‐G) score was 6 (range, 0–27); and 36% had impairment in activities of daily living (ADL). The most common induction regimens were high‐dose methotrexate (HD‐MTX) ± rituximab; methotrexate, temozolomide, rituximab (MTR); and rituximab, methotrexate, procarbazine, vincristine (R‐MPV). Overall, 70% of patients achieved remission, with 14% undergoing consolidative autologous stem cell transplant (ASCT) and 24% receiving maintenance. With 58‐month median follow‐up, median progression‐free survival (PFS) and overall survival (OS) were 17 months (95% CI 13–22 months) and 43 months (95% CI 31–56 months), respectively. Three‐year PFS and OS were highest with MTR (55% and 74%, respectively). With single‐agent methotrexate ± rituximab, 3‐year PFS and OS were 30% ( p = .0002) and 47% ( p = .0072). On multivariate analysis, increasing age at diagnosis and Cooperative Oncology Group (ECOG) performance status (PS) was associated with inferior PFS; age, hypoalbuminemia, higher CIRS‐G score, and ECOG PS adversely affected OS. Among patients receiving maintenance, 3‐year PFS was 65% versus 45% without maintenance ( p = 0.02), with 3‐year OS of 84% versus 61%, respectively ( p = .0003). Altogether, outcomes in older PCNSL patients appeared optimized with HD‐MTX combination induction regimens and maintenance therapy. Furthermore, several prognostic factors, including geriatric measures, were associated with inferior outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LymphomaCentral Nervous System NeoplasmsHumansAgedMiddle AgedAged, 80 and overRituximabMethotrexateAntineoplastic Combined Chemotherapy ProtocolsCytarabineActivities of Daily LivingRetrospective StudiesTemozolomideCentral Nervous System

Substanzen

RituximabMethotrexateCytarabineTemozolomide

Autor:innen und Institutionen

  • Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
  • Roswell Park Cancer Institute, Buffalo, New York, USA.
  • Rush University Medical Center, Chicago, Illinois, USA.
  • Penn State Cancer Institute, Hershey, Pennsylvania, USA.
  • John Theurer Cancer Center, Hackensack, New Jersey, USA.
  • Washington University in St. Louis, St. Louis, Missouri, USA.

ORCID-Profile: Kevin A David, Mary-Kate Malecek, Adam Zayac, Douglas Ney, Veronika Bachanova, Ajay Major, Angel Mier-Hicks, Pallawi Torka, Samuel A Goldlust, Thomas A Ollila, Narendranath Epperla, Reem Karmali, Andrew M Evens

Förderung

  • NCI NIH HHS

Zitieren

APA

David, K. A., Sundaram, S., Kim, S. H., Vaca, R., Lin, Y., Singer, S., Malecek, M. K., Carter, J., Zayac, A., Kim, M. S., Reddy, N., Ney, D., Habib, A., Strouse, C., Graber, J., Bachanova, V., Salman, S., Vendiola, J. A., Hossain, N., …, & Evens, A. M. (2023). Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers. American Journal of Hematology. https://doi.org/10.1002/ajh.26919

Vancouver

David KA, Sundaram S, Kim SH, Vaca R, Lin Y, Singer S, et al. Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers. American Journal of Hematology. 2023. doi:10.1002/ajh.26919

BibTeX
@article{David2023,
  author = {David, Kevin A and Sundaram, Suchitra and Kim, Seo-Hyun and Vaca, Ryan and Lin, Yong and Singer, Samuel and Malecek, Mary-Kate and Carter, Jordan and Zayac, Adam and Kim, Myung Sun and Reddy, Nishitha and Ney, Douglas and Habib, Alma and Strouse, Christopher and Graber, Jerome and Bachanova, Veronika and Salman, Sidra and Vendiola, Jean Alyxa and Hossain, Nasheed and Tsang, Mazie and Major, Ajay and Bond, David A and Agrawal, Prashasti and Mier-Hicks, Angel and Torka, Pallawi and Rajakumar, Priya and Venugopal, Parameswaran and Berg, Stephanie and Glantz, Michael and Goldlust, Samuel A and Folstad, Matthew and Kumar, Pallavi and Ollila, Thomas A and Cai, Johnny and Spurgeon, Stephen and Sieg, Alex and Cleveland, Joseph and Chang, Julie and Epperla, Narendranath and Karmali, Reem and Naik, Seema and Martin, Peter and Smith, Sonali M and Rubenstein, James and Kahl, Brad and Evens, Andrew M},
  title = {Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers},
  journal = {American Journal of Hematology},
  year = {2023},
  doi = {10.1002/ajh.26919}
}
Kostenlos starten →